---
title: "Interactions Between HIV-1 Broadly Neutralizing Antibodies and Natural Killer Cells: Systematic Re"
id: "frontiers-in-immunology-13-bidirectional-interactions-between-hiv-1-broadly-neutralizing-antibodies-and"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-bidirectional-interactions-between-hiv-1-broadly-neutralizing-antibodies-and"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973968"
published_at: "2026-11-11T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Interactions Between HIV-1 Broadly Neutralizing Antibodies and Natural Killer Cells: Systematic Re
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-bidirectional-interactions-between-hiv-1-broadly-neutralizing-antibodies-and
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973968)
- **Published At:** 2026-11-11T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The article is a systematic review examining bidirectional interactions between **HIV-1** **broadly neutralizing antibodies** (bnAbs) and **natural killer cells** across antibody development and effector phases. - The source name is Frontiers in Immunology; the review scope centers on adaptive–innate cross-talk in HIV-1 antibody biology. - The review focuses on two distinct phases: antibody development (how NK cells may influence bnAb generation) and effector phases (how bnAbs recruit or modulate NK cell function). - The published abstract and page metadata were available, but the SOURCE did not report detailed methods, study selection criteria, or quantitative results in the provided content. - The SOURCE did not include specific findings, pooled effect sizes, or trial endpoints in the text provided to us; detailed mechanisms, clinical correlates, and experimental models referenced in the review are not present in the supplied material. - Because methodological and result-level details were not provided, direct appraisal of evidence strength, biases, or recommendations for clinical translation cannot be drawn from the provided SOURCE. - The review’s topic implies relevance for vaccine design and antibody-based therapies seeking to harness NK-mediated effector functions, yet the SOURCE did not state explicit implications or next regulatory milestones. - Key unanswered questions remaining in the supplied content include which NK subsets drive bnAb maturation, how Fc receptor interactions modulate bnAb efficacy, and what standardized assays the review recommends; the SOURCE did not report answers to these points. - The supplied SOURCE content is limited to title, journal header, and navigation elements; investigators reported the existence of a systematic review, but the SOURCE did not report study-level data in the excerpt provided. - Readers should consult the full Frontiers in Immunology article for complete methods, results, and the authors’ conclusions, since those elements were not included in the SOURCE material supplied here.
## Clinical Analysis & Structured Key Points
Frontiers | Bidirectional Interactions Between HIV-1 Broadly Neutralizing Antibodies and Natural Killer Cells in Antibody Development and Effector Phases: A Systematic Review SYSTEMATIC REVIEW article Front. Immunol. Sec. Viral Immunology Volume 17 - 2026 | doi: 10.3389/fimmu.2026.1973968 Published in Frontiers in Immunology Viral Immunology 7 impact factor 11.3 citescore Reviewers Reviewed by 2 A 2 Anonymous reviewers Outline SYSTEMATIC REVIEW article Front. Immunol. Sec. Viral Immunology Bidirectional Interactions Between HIV-1 Broadly Neutralizing Antibodies and Natural Killer Cells in Antibody Development and Effector Phases: A Systematic Review J Z Jiaxin Zhen 1 W C Wenhui Cao 1 J W Jing Wei 2 X S Xuanling Shi 2 H W Hui Wang 1 Y L Yixiao Li 1 Y H Yihui He 1 Y C Yingyi Cong 1 Y W Yuekui Wang 1 Z F Zhen Fang 1 H Z Hanxu Zhu 1 P W Pei Wang 1 +4 more X H Xiaojie Huang 1 1. Department of Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China 2. Comprehensive AIDS Research Center, Pandemic Research Alliance Unit, Center for Infection Biology, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, China, Beijing, China Article metrics View details The final, formatted version of the article will be published soon. Notify me Select one of your emails You have multiple emails registered with Frontiers: Notify me Notify me on publication Please enter your email address: Email If you already have an account, please login You don't have a Frontiers account ? You can register here Notify me Abstract Broadly neutralizing antibodies (bNAbs) are increasingly investigated for HIV-1 prevention and treatment. bNAbs have both direct neutralizing activity and Fc-dependent effector functions. Natural killer (NK) cells are important Fc-dependent effectors, but their interactions with bNAbs remain incompletely understood. This systematic review evaluated the bidirectional relationship between NK cells and HIV-1 bNAbs, focusing on natural bNAb development and interactions involving mature bNAbs. Following PRISMA 2020, PubMed, Web of Science, and Embase were searched from inception through August 10, 2026. A total of 40 studies met the eligibility criteria. Findings were synthesized narratively because of substantial heterogeneity. Evidence on the role of NK cells in bNAb development was limited and mainly observational. NK cell subset distribution, RAB11FIP5 expression, degranulation, and cytokine responses were associated with neutralization breadth, without establishing causality. Evidence was stronger for the effector phase. bNAbs induced NK cell degranulation and cytokine production and mediated NK cell-dependent killing of infected cells. These responses varied among bNAbs and were influenced by antibody properties, NK cell subset and differentiation phenotype, and viral, target cell, microenvironmental, and experimental factors. Enhanced NK cell activity did not necessarily translate into greater protection in vivo. The evidence provides stronger support for NK cell effector responses involving mature bNAbs, whereas a causal role for NK cells in natural bNAb development remains unestablished. Future studies should clarify whether NK cells causally influence bNAb development and under what conditions NK cell engagement provides additional antiviral benefit beyond direct neutralization. Summary Keywords broadly neutralizing antibodies, Fc effector function, HIV, HIV cure, Natural Killer cells, neutralization breadth Received 20 August 2026 Accepted 29 October 2026 Copyright © 2026 Zhen, Cao, Wei, Shi, Wang, Li, He, Cong, Wang, Fang, Zhu, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Xiaojie Huang Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Article metrics View details Share article Our quality Expert judgment makes science stronger Behind every published article stand expert reviewers safeguarding science. Discover our rigorous approach to peer review. Learn about peer review Outline Share article Facebook X LinkedIn Email WeChat Share on WeChat Scan with WeChat to share this article Article metrics
## Related Clinical Research

- [Innate immune states linked to different serological responses after syphilis treatment](https://medichelpline.com/clinical-feed/biorxiv-3-distinct-innate-immune-states-associate-with-divergent-serological-outcomes.md)
- [Methamphetamine reshapes immune cell and plasma signatures in people with HIV](https://medichelpline.com/clinical-feed/medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage.md)
- [EmERGE mHealth for HIV care: sustained patient activation and safety over 3.2 years](https://medichelpline.com/clinical-feed/pubmed-43059328.md) (DOI: 10.1080/25787489.2026.2759372)
- [Whole-exome analysis of HIV-associated genes in the Mizo population, Northeast India](https://medichelpline.com/clinical-feed/pubmed-42542174.md) (DOI: 10.1016/j.gene.2026.150334)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.